Abstract: The invention relates to condensed cyclic triazole derivatives of the general Formula I ##STR1## and pharmaceutically acceptable salts thereof. The compounds of the general Formula I possess useful sedative and tranquillant properties and exhibit particularly spasmolytic, motility inhibiting, and narcosis potentiating, yohimbine potentiating and local anaesthetic and also weak reserpine ptosis inhibiting effect.

Abstract: It has been found that 2-methyl-thiazolo[4,5-c]quinoline and pharmaceutically acceptable acid addition salts and hydrates thereof possess valuable central nervous depressive properties being different from those of benzodiazepines. The invention relates to pharmaceutical compositions comprising as active ingredient 2-methyl-thiazolo[4,5-c]quinoline of the Formula I ##STR1## or a pharmaceutically acceptable acid addition salt or hydrate thereof.

Abstract: The invention relates to new compounds of the general Formula I ##STR1## and isomers thereof wherein R.sub.1 is C.sub.1-10 alkyl, C.sub.3-6 cycloalkyl or phenyl, naphthyl or phenyl-(C.sub.1-4 alkyl), wherein the aryl ring of the three latter groups may optionally bear one or more halogen, nitro, trifluoromethyl, amino, hydroxy, C.sub.1-4 alkyl and/or C.sub.1-4 alkoxy substituent(s);R.sub.2 stands for hydrogen, halogen, hydroxy, oxo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, phenyl or naphthyl, wherein the two latter groups may optionally bear one or more halogen, nitro, trifluoromethyl, amino, hydroxy, C.sub.1-4 alkyl and/or C.sub.1-4 alkoxy substituent(s);R.sub.3 represents hydrogen, hydroxy or C.sub.1-4 alkoxy;Z is buta-1,3-dienyl or a group of the general Formula (a) ##STR2## or (b) ##STR3## and X is hydrogen or halogen.The compounds of the general Formula I possess useful pharmacological properties, particularly antidepressant and antiarrhythmial effect.

Abstract: The invention relates to selected stereoisomers having the E, E or E, Z configuration and within the Formula (I) ##STR1## wherein N is 2-4, A is alkylene or 2 or 3 carbon atoms, R is phenyl or substituted phenyl and R.sup.1 and R.sup.2 are lower alkyl, or, together with the carbon to which attached, form a heterocyclic ring; and pharmaceutically acceptable acid addition salts thereof, a process for their preparation and pharmaceutical compositions comprising the same.The compounds of the general formula (I) can be used in therapy due to their narcosis potentiating, analgesic and antiarrhythmial effect.

Abstract: A one step process for the preparation of compounds having antidepressant activity of the formula I ##STR1## and isomers thereof, wherein R.sub.1, R.sub.2, Z and A.sup.- have the meanings indicated in the claims, which process comprises: heating a compound of the formula II ##STR2## wherein Z, A.sup.-, R.sub.1 and R.sub.2 have the meanings set out in the claims and R.sub.3 stands for hydrogen or C.sub.1-4 alkyl, in the presence of a dehydrating agent to split off a compound of the formula R.sub.3 OH. The invention is also directed to compounds of the formula I, wherein R.sub.2 is halogen and to compositions containing a compound of the formula I which exhibit antidepressant activity.

Abstract: The invention relates to novel iminothiazolidine derivatives of the formula (I), ##STR1## wherein R.sup.1 and R.sup.3 represent, independently from each other, hydrogen or lower alkyl group,R.sup.3 is nitro or amino group,R stands for halo, lower alkyl, haloalkyl, nitro, amino, hydroxy, lower alkoxy, carboxy or lower alkoxycarbonyl group, andn is 0, 1 or 2,and pharmaceutically acceptable acid addition salts thereof.The iminothiazolidine derivatives of the formula (I) possess valuable antidepressant, antiparkinsonic, antiepileptic and spasmolytic activities.

Abstract: The invention relates to new quinoline derivatives of the general Formula I ##STR1## (wherein X stands for hydrogen, halogen or lower alkoxy;n is an integer of 1, 2 or 3;R.sup.1 represents hydrogen andR.sup.2 represents hydroxy-lower alkyl or lower alkoxy-lower alkyl or a group of the general formula IV, ##STR2## wherein Z stands for --O--, --S--, --NH-- or --N(lower alkyl)--; the dotted lines represent optional bonds; andm is 0 or 1; orR.sup.1 and R.sup.2 together with the adjacent nitrogen atom, they are attached to, form a 5- or 6-membered heterocyclic group which may optionally contain a further oxygen, nitrogen or sulfur heteroatom and may be optionally substituted),and pharmaceutically acceptable acid addition salts thereof. The new compounds of the present invention exhibit radiosensitizing effect, make hypoxial cells highly sensitive towards radiation and may be used in radiation therapy.

Abstract: The invention relates to pharmaceutical compositions possessing valuable antianginal activity. These compositions show higher activity and more favorable therapeutic indices than the reference compound Prenylamine. Preparation of different kinds of pharmaceutical compositions, such as tablets, dragees, capsules and injectable solutions, containing compounds of general formula (I) ##STR1## or their acid addition salts as active ingredients, is disclosed, wherein in formula (I)R is phenyl or 4-chlorophenyl;R.sup.1 and R.sup.2 each represent hydrogen, methyl or isopropyl;R.sup.3 and R.sup.4 are hydrogen, or together form a chemical bond;n is an integer from 4 to 6;A means trimethylene, if n is 4 or 6; or ethylene, if n is 5.

Abstract: Acylated pyrido ?3,4-e!-as-triazines of the formula (I), ##STR1## wherein R.sub.1 stands for alkyl, alkoxy, haloalkyl, furyl, pyridyl, phenyl, phenyl-(C.sub.1-4 alkyl) or phyenyl-(C.sub.2-4 alkenyl) optionally substituted. R.sub.2 stands for hydrogen or a group of the formula R.sub.1 --CO--, R.sub.3 stands for hydrogen, a phenyl group or a naphthy6l group optionally substituted, or a phenyl-(C.sub.1-4 alkyl) group, pyridyl group or a C.sub.1-20 alkyl group, and R.sub.4 stands for hydrogen or a group of the formula R.sub.1 --CO--, and R.sub.5 forms together with R.sub.2 or R.sub.4 a valence bond, wherein R.sub.2 or R.sub.4 taking part in forming said valence bond may not have the above meaning, and pharmaceutically acceptable acid addition salts thereof, which are prepared by reacting a pyrido ?3,4-e!-as-triazine of the formula (II) or an acid addition salt thereof ##STR2## R.sub.6 stands for hydrogen, and R.sub.5 forms together with R.sub. and R.sub.

Abstract: The invention relates to new condensed as-triazine derivatives of the general formula (I) ##STR1## wherein Z represents a buta-1,3-dienyl group or a group of the formula (a), (b), (c) or (d) ##STR2## R.sub.1 denotes a C.sub.1-10 alkyl group, an oxo group or a C.sub.6-10 aryl or C.sub.6-10 aryl-(C.sub.1-3 alkyl) group optionally substituted by one or more identical or different substituents selected from the group consisting of amino, nitro, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy and halogen,R.sub.2 stands for hydrogen, C.sub.1-10 alkyl or amino,R.sub.3 represents hydrogen, C.sub.1-10 alkyl or C.sub.6-10 aryl or C.sub.6-10 aryl-(C.sub.1-3 alkyl) optionally substituted by one or more identical or different substituents selected from the group consisting of nitro, amino, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy and halogen,X.sup.- denotes an anion, andn is 0 or 1,with the proviso that if n is O, R.sub.1 is other than an oxo group and R.sub.1 ' and R.sub.

Abstract: The invention relates to novel oxime ethers of the general formula /I/ and acid addition salts and quaternary ammonium derivatives thereof, ##STR1## wherein A represents a C.sub.2-6 straight or branched alkylene chain,R and R.sup.1 each represent a C.sub.1-6 alkyl group or they form together with the adjacent nitrogen atom a heterocyclic ring containing 4 to 7 carbon atoms and optionally a further hetero atom, i.e. an oxygen, sulfur or nitrogen atom, and said ring may be optionally substituted by a C.sub.1-3 alkyl, phenyl or benzyl group,R.sup.2 and R.sup.3 each denote a hydrogen atom or together form a valency bond,R.sup.4 denotes a C.sub.1-10 alkyl or C.sub.2-10 alkenyl group, andn denotes an integer from 3 to 7.The compounds of the general formula /I/ are prepared according to the invention by reacting a cycloalkane derivative of the general formula /II/ ##STR2## wherein R.sup.2, R.sup.3, R.sup.4 and n have the same meaning as above, whereasY denotes an oxygen or sulphur atom or a .dbd.

Abstract: The invention relates to novel basic ethers of the general formula /I/ and pharmaceutically acceptable acid addition salts and quaternary salts thereof, ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different and represent a C.sub.1-5 alkyl group or a C.sub.3-6 cycloalkyl group or they form, together with the adjacent nitrogen atom, a heterocyclic ring containing 4-7 carbon atoms and optionally a further hetero atom, e.g. an oxygen, sulfur or nitrogen atom, and this latter may be optionally substituted by a C.sub.1-3 alkyl, benzyl or phenyl group,R represents a phenyl, phenyl-/C.sub.1-3 alkyl/ or thienyl group optionally substituted by one or more halogen or C.sub.1-3 alkoxy substituent/s/,A represents a C.sub.2-5 straight or branched alkylene chain, and represents a valence bond of .alpha. or .beta. configuration.

Abstract: New compounds are disclosed of the formulae ##STR1## or pharmaceutically effective salts thereof, wherein R is hydrogen, C.sub.1-12 alkyl, or R is phenyl or phenyl-C.sub.1 to C.sub.4 alkyl wherein the phenyl can be substituted with 1 to 3 halogen, C.sub.1 to C.sub.4 alkyl, or C.sub.1 to C.sub.4 alkoxy substituents; andX.sub.1, X.sub.2 and X.sub.3 are hydrogen, C.sub.1 to C.sub.6 alkanoyl, or C.sub.1 to C.sub.6 haloalkanoyl; and where X.sub.1 is hydrogen, X.sub.2 and X.sub.3 are not simultaneously hydrogen. The compounds possess antiphlogistic, analgesic, anticonvulsive, or tranquilizing properties.

Abstract: New pyrido[2,3-e]-as-triazine derivatives of the general formula (I), ##STR1## wherein R.sup.1 and R.sup.2 each stand for a C.sub.1-20 alkylcarbonyl, halogenated (C.sub.1-4 alkyl)-carbonyl, C.sub.1-4 alkoxycarbonyl, benzoyl, phenyl-(C.sub.1-4 alkyl)-carbonyl or phenyl-(C.sub.2-4 alkenyl)-carbonyl group or a 5-10-membered mono- or bicyclic nitrogen-containing heterocyclic acid residue (preferably a pyridylcarbonyl group) containing optionally one or more additional nitrogen, oxygen and/or sulfur atoms in the heterocyclic ring, and optionally one or more identical or different substituents selected from the group consisting of halogen, C.sub.1-4 alkoxy, nitro and hydroxy are attached to the aromatic or heterocyclic rings, furthermore one of R.sup.1 and R.sup.2 may also stand for hydrogen atom, orR.sup.1 and R.sup.2 may form, together with the adjacent nitrogen atoms, a pyrazole-2,4 ring having optionally a C.sub.1-6 alkyl substituent in position 3, andR.sup.3 stands for hydrogen, halogen, C.sub.

Abstract: Novel aminoisoquinoline derivatives of the general formula (I) ##STR1## wherein R.sub.1 represents a hydrogen atom or a C.sub.1-4 alkyl group,R.sub.2 represents a hydrogen atom,R.sub.3 represents a hydrogen atom,R.sub.4 represents a morpholinyl group or a piperazinyl group substituted with a pyridyl group, andpharmaceutically acceptable acid addition salts and quaternary derivatives thereof have been prepared. The novel compounds exert narcosis potentiating effects.

Abstract: The invention relates to new pyrido[3,2-e]-as-triazine derivatives of the formula I and pharmaceutically acceptable acid addition salts thereof, ##STR1## wherein R.sub.1 stands for a C.sub.1-20 alkyl-carbonyl group, halogen-C.sub.1-4 alkyl-carbonyl, benzoyl, phenyl-C.sub.1-4 alkyl-carbonyl, or pyridyl-carbonyl group;R.sub.2 is a hydrogen atom or a C.sub.1-4 alkyl-carbonyl group; or R.sub.1 and R.sub.2 form together with the adjacent nitrogen atoms a pyrazole-2,4-dione ring which carries a C.sub.1-6 alkyl substituent in position 3;R.sub.3 is a hydrogen atom, a C.sub.1-20 alkyl, phenyl, phenyl-C.sub.1-3 alkyl, furyl or pyridyl group or a phenyl group optionally substituted by one to three C.sub.1-4 alkoxy-groups.The compounds of the formula I are prepared by acylating the respective 1,2-un-substituted 1,2-dihydropyrido [3,2-e]-as-triazine derivatives. The new compounds exert valuable effects on the central nervous system and possess analgesic, antiphlogistic effects, and can be applied to advantage in therapy.

Abstract: The invention relates to new benzo-as-triazine derivatives of the formulae (I) and (Ia) and pharmaceutically acceptable acid addition salts thereof, ##STR1## wherein R.sub.1 and R.sub.2 each represent hydrogen, a C.sub.1-20 alkylcarbonyl group, a phenylcarbonyl or phenyl-(C.sub.1-4 alkyl)-carbonyl group having optionally one or more halogen, hydroxy or C.sub.1-3 alkoxy substituents which may be the same or different, furthermore a pyridylcarbonyl, a pyrazinylcarbonyl, a furylcarbonyl, a chloroacetyl or a C.sub.1-4 alkoxycarbonyl group, orR.sub.1 and R.sub.2 may form, together with the adjacent nitrogen atoms, a pyrazole ring having optionally a C.sub.1-6 alkyl substituent in position 4,with the proviso that one of R.sub.1 and R.sub.2 is always different from hydrogen,R.sub.3 stands for hydrogen, mercapto group, a C.sub.1-4 alkylmercapto group, amino group, a C.sub.1-4 alkylamino group, a piperazino group having optionally an N-alkyl or 2-pyridyl substituent, a morpholino group or a piperidino group, andR.sub.

Abstract: The invention relates to novel pyrazolo[1,5-c]quinazoline derivatives of the general formula I ##STR1## wherein R represents a hydrogen atom, a C.sub.1-4 alkyl group or an acyl group,R.sub.1 represents a hydrogen atom, a C.sub.1-12 alkyl group, a C.sub.3-8 cycloalkyl group, a C.sub.2-4 alkenyl group, an aralkyl group, wherein the alkyl group has 1 to 4 carbon atoms, a phenylalkenyl group, wherein the alkenyl group has 2 to 4 carbon atoms, furthermore a carboxy group or a phenyl group optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C.sub.1-4 alkoxy, nitro or di(C.sub.1-4 alkyl)amino groups, orR and R.sub.1 may form together a valence bond,R.sub.2 represents a hydrogen atom, a C.sub.1-4 alkyl or a phenyl group, orR.sub.1 and R.sub.2 may form together a C.sub.2-7 alkylene group,R.sub.

Abstract: The invention relates to novel cyclododecane derivatives of the general formula ##STR1## wherein R.sup.1 and R.sup.2 represent independently from each other a hydrogen atom, a C.sub.1-6 alkyl group or a C.sub.3-8 cycloalkyl group, or R.sup.1 and R.sup.2 form together with the nitrogen atom to which they are attached a heterocyclic ring containing 4 to 7 carbon atoms and optionally a further heteroatom selected from the group consisting of oxygen, sulphur and nitrogen, said ring may be optionally substituted by a C.sub.1-3 alkyl or benzyl group; and A represents a C.sub.2-6 straight or branched alkylene chain, and optically active isomers, acid addition salts and quaternary ammonium derivatives thereof. The invention relates further to an analogous process for the preparation of said compounds, to pharmaceutical compositions containing said compounds as the active ingredient and to a process for the preparation of said pharmaceutical compositions.

Abstract: The invention relates to novel 1-phenyl-2-amino-1,3-propanediol-N-alkyl derivatives having the general formula I ##STR1## wherein R.sub.1 is hydrogen, alkyl having from 1 to 8 carbon atoms or phenoxymethyl, andR.sub.2 is hydrogen, alkyl having from 1 to 8 carbon atoms or 2,2-diphenylethyl,with the proviso that if R.sub.1 is phenoxymethyl then R.sub.2 may stand only for methyl, and if R.sub.2 is 2,2-diphenylethyl then R.sub.1 may stand only for hydrogen, and its isomers and pharmaceutically acceptable salts. Furthermore, the invention relates to a process for preparing these compounds.The novel 1-phenyl-2-amino-1,3-propanediol-N-alkyl derivatives having the general formula I possess significant anti-anginose activity and show several other biological activities.